Roxall Medizin
ROXALL Group is a private specialty pharmaceutical company developing and distributing prescription allergy immunotherapy treatments across six European countries, serving allergologists, pharmacies, wholesalers, and patients via direct sales and its RoxVac order-tracking platform.
- Company typePrivate
- Founded1994
- HeadquartersHamburg, Germany
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Roxall Medizin does
ROXALL Group is a privately held specialty pharmaceutical company focused on allergology and immunotherapy, claiming approximately 30 years of innovation in the field (founded circa 1994). The company develops and distributes prescription allergy immunotherapy treatments, positioning immunotherapy as its flagship offering, and serves allergologists, immunology specialists, pharmacies, wholesalers, and patients across six European countries: Spain, Germany, Austria, Italy, Portugal, and Turkey. Its operational headquarters is located in the Zamudio Technology Park in Bizkaia, Spain.
The company's product portfolio is centered on its allergy immunotherapy treatments, with a secondary digital offering in RoxVac—a pharmacy-facing real-time order tracking and management platform launched in 2023 that allows pharmacies and wholesalers to register vaccine orders, monitor delivery status, and access product and batch information. ROXALL also maintains a gated professional area portal for healthcare providers, which includes a portfolio, an events calendar, and a Hymenoptera Blog, alongside a patient-facing section covering allergy education and order tracking.
ROXALL's go-to-market relies on direct sales representatives engaging allergologists and immunology specialists, supported by country-specific localized websites in each European market, professional events and conferences, and distribution through pharmacies and wholesalers. The company emphasizes R&D as part of its identity and has a pharmacovigilance and ethical channel consistent with regulated pharmaceutical operations. No funding rounds, M&A activity, partnerships, or revenue figures are disclosed in the available data.
Roxall Medizin firmographics
Firmographics- Name
- Roxall Medizin
- Legal name
- ROXALL Group
- Website
- https://roxall.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ROXALL Group is a private specialty pharmaceutical company developing and distributing prescription allergy immunotherapy treatments across six European countries, serving allergologists, pharmacies, wholesalers, and patients via direct sales and its RoxVac order-tracking platform.
- Ownership category
- akta.pro rank
Roxall Medizin industry classification
Industry- Product category
- Specialty Allergy Immunotherapy Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)
Keywords
Where Roxall Medizin is headquartered
LocationHeadquarters
- HQ city
- Hamburg
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Roxall Medizin business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Immunotherapy Products: Specialty allergy immunotherapy treatments sold to healthcare providers, pharmacies, and patients. The company focuses on the specialty allergology market with immunotherapy as its flagship offering.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Roxall Medizin product offering
Product offeringCore offering
ROXALL Group is an international specialty pharmaceutical company that develops and distributes prescription allergy immunotherapy treatments (vaccines) for the treatment of allergic conditions. Its products are sold through pharmacies and wholesalers across six European countries, complemented by RoxVac, a proprietary pharmacy-facing platform for real-time order registration and delivery tracking.
Product overview
ROXALL Group is a specialty pharmaceutical company focused on allergology and immunotherapy. The company operates two main offerings: its core immunotherapy product portfolio for treating allergies, and RoxVac, a pharmacy order management and tracking platform that allows pharmacies to register orders and monitor delivery status in real-time. The company maintains a professional area for healthcare providers alongside its patient-facing services.
Differentiator
Problem solved
Functional benefit
Brands
- RoxVac: Platform enabling pharmacies to register and track vaccine orders in real-time.
Products and services
- ROXALL Allergy Immunotherapy Portfolio
Companies that use Roxall Medizin
Customer profileSegments3 records
Ideal customer profiles3 records
Roxall Medizin technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Roxall Medizin partnerships and signals
Strategic signalScale indicators2 records
Recent moves4 records
Expansion highlights4 records
Roxall Medizin competitors and assessment
Company assessmentDirect peers
- ALK-Abelló: Global leader in allergy immunotherapy, headquartered in Denmark. Directly competes with ROXALL in prescription allergen-specific immunotherapy for respiratory and venom allergies, serving the same allergologist and pharmacy channels across Europe.
- Stallergenes Greer: Specialty immunotherapy company focused on allergy diagnosis and treatment, now majority-owned by Bertelli. Competes head-to-head with ROXALL in subcutaneous and sublingual immunotherapy across European markets.
- Allergy Therapeutics: UK-listed specialty pharma developing and commercialising allergy vaccines and diagnostics. Closely comparable product portfolio, therapeutic focus, and European distribution model to ROXALL.
- HAL Allergy: Dutch-German specialty allergen manufacturer producing diagnostic and immunotherapy products. Direct overlap with ROXALL in venoms, pollens, and indoor allergens sold through European pharmacies and allergists.
- Leti Pharma: Spanish-based specialty pharma with deep focus on allergy diagnostics and immunotherapy. Strong overlap with ROXALL's home market (Spain) and therapeutic positioning.
Emerging players
- Biomay: Vienna-based biotech specializing in recombinant allergen immunotherapy and peptide vaccines. Smaller and more pipeline-stage than ROXALL but directly comparable therapeutic category and European footprint.
- Anergis: Swiss clinical-stage company developing synthetic peptide vaccines for birch and other pollen allergies. Comparable therapeutic mechanism and target prescribers but currently pre-commercial versus ROXALL's established portfolio.
- DBV Technologies: French biotech developing epicutaneous immunotherapy patches for food and respiratory allergies. Competes for the same allergologist mindshare and represents a potential modality disruptor to injectable immunotherapy.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Roxall Medizin social profiles
Digital presenceRoxall Medizin financial estimates
Financial estimateRevenue estimate
Valuation estimate
Roxall Medizin leadership team
Management profileNumber of profiles
Roxall Medizin subsidiaries and ownership
Company hierarchySubsidiaries1 record
Roxall Medizin funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Roxall Medizin M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Roxall Medizin
What does Roxall Medizin do?
ROXALL Group is an international specialty pharmaceutical company that develops and distributes prescription allergy immunotherapy treatments (vaccines) for the treatment of allergic conditions. Its products are sold through pharmacies and wholesalers across six European countries, complemented by RoxVac, a proprietary pharmacy-facing platform for real-time order registration and delivery tracking.
Is Roxall Medizin a public or private company?
Roxall Medizin is a private company. It is classified as unknown and is currently operating.
When was Roxall Medizin founded?
Roxall Medizin was founded in 1994. It employs 1 to 10 people.
Where is Roxall Medizin based?
Roxall Medizin is headquartered in Hamburg, Germany, in the Europe region.
How does Roxall Medizin make money?
One revenue line is on record: immunotherapy Products.
Who are Roxall Medizin's main competitors?
Direct peers on record are ALK-Abelló, Stallergenes Greer, Allergy Therapeutics, HAL Allergy and Leti Pharma. Emerging players are Biomay, Anergis and DBV Technologies.
Does Roxall Medizin have an API?
No public API is recorded for Roxall Medizin.
What industry is Roxall Medizin in?
Roxall Medizin's product category is Specialty Allergy Immunotherapy Pharmaceuticals. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.